Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AGER | Q15109 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6950669 | 0.80 | ACHE (0.40) | MEN1KMT2AALDH1A1 | |
| SCHEMBL16572213 | 0.79 | TAAR1 (0.38) | TAAR1HTR2ACYP2A6IDO1MEN1 | |
| SCHEMBL11648 | 0.77 | TAAR1 (0.37) | TAAR1HTR2ACYP2A6IDO1MEN1 | |
| SCHEMBL15314314 | 0.76 | IDO1 (0.42) | TAAR1CYP2A6IDO1MEN1KMT2A | |
| SCHEMBL14935121 | 0.76 | SLC6A4 (0.50) | TAAR1HTR2ACYP2A6IDO1MEN1 | |
| SCHEMBL2489390 | 0.75 | TSHR (0.50) | TAAR1IDO1 | |
| SCHEMBL20076110 | 0.75 | CHRM3 (0.46) | IDO1 | |
| SCHEMBL1737226 | 0.71 | ESR1 (0.43) | TAAR1HTR2ACYP2A6IDO1ALOX15 | |
| SCHEMBL14935113 | 0.71 | TAAR1 (0.35) | TAAR1HTR2ACYP2A6IDO1MEN1 | |
| SCHEMBL3269847 | 0.71 | ALDH1A1 (0.48) | TAAR1IDO1ALOX15ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10197881-B2 | Complimentary polymer electrochromic device | ASHWIN-USHAS CORPORATION, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170184936-A1 | Complimentary Polymer Electrochromic Device | ASHWIN-USHAS CORP INC (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170184936-A1 | Complimentary Polymer Electrochromic Device | ASHWIN-USHAS CORP INC (US) | 2017-06-29 | — | — | US | disclosed |
| EP-2780762-B1 | COMPLIMENTARY POLYMER ELECTROCHROMIC DEVICE | ASHWIN-USHAS CORP INC (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2780762-B1 | COMPLIMENTARY POLYMER ELECTROCHROMIC DEVICE | ASHWIN-USHAS CORP INC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9594284-B2 | Complimentary polymer electrochromic device | ASHWIN-USHAS CORPORATION, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9594284-B2 | Complimentary polymer electrochromic device | ASHWIN-USHAS CORPORATION, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9274395-B2 | Complimentary polymer electrochromic device | ASHWIN-USHAS CORPORATION, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9274395-B2 | Complimentary polymer electrochromic device | ASHWIN-USHAS CORPORATION, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150275385-A1 | COMPLIMENTARY POLYMER ELECTROCHROMIC DEVICE | ASHWIN USHAS CORP INC (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150275385-A1 | COMPLIMENTARY POLYMER ELECTROCHROMIC DEVICE | ASHWIN USHAS CORP INC (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2780762-A1 | COMPLIMENTARY POLYMER ELECTROCHROMIC DEVICE | Ashwin-Ushas Corporation, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013074702-A1 | COMPLIMENTARY POLYMER ELECTROCHROMIC DEVICE | ASHWIN-USHAS CORPORATION, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20130120821-A1 | COMPLIMENTARY POLYMER ELECTROCHROMIC DEVICE | ASHWIN-USHAS CORPORATION, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| EP-1115729-B1 | PHOSPHONIC ACID DERIVATIVES AS INHIBITORS OF PTP-1B | MERCK FROSST CANADA INC (CA) | 2003-02-19 | — | — | EP | disclosed |
| US-6174874-B1 | ANTIDIABETIC,-CARCINOGENIC AGENTS; IMPROVING GLUCOSE TOLERANCE/INSULIN-SENSITIVITY; PREVENTING/TREATING OBESITY AND NEURODEGENERATIVE DISEASES; E.G. 1,3-BIS-((PHOSPHONODI-FLUOROMETHYL)PHENYL)-2-DICARBOXYPROPANE | MERCK FROSST CANADA & CO. (CA) | 2001-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10197881-B2 | Complimentary polymer electrochromic device | PMS2, PARG, EED | TAAR1 3131/4885HTR2A 1863/4885CYP2A6 3894/4885 |
| US-20130120821-A1 | COMPLIMENTARY POLYMER ELECTROCHROMIC DEVICE | PMS2, PARG, EED | TAAR1 3131/4885HTR2A 1863/4885CYP2A6 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.